# A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

Source: https://onco.cc/trials/nct06764940/  
OnCo record `nct06764940` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Capecitabine in brain and spinal cord tumours, run by Biostar Pharma, Inc., now recruiting.

## Summary

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases is a phase 2 interventional study registered as NCT06764940 by Biostar Pharma, Inc., with 120 participants planned, started 2025-07-14 and due to reach its primary completion in 2027-01-15. Interventions recorded: Utidelone and Utidelone in combination with capecitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06764940
- Phase: 2
- Setting: A Pivotal Phase II Clinical Trial of Utidelone Injection (UTD1) Plus Capecitabine (CAP) in HER2-negative Breast Cancer Patients With Brain Metastases
- Sponsor: Biostar Pharma, Inc.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06764940: https://clinicaltrials.gov/study/NCT06764940

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/)

---
JSON: https://onco.cc/api/v1/entities/nct06764940.json